Stopping Wegovy without weight regain

Semaglutide carries no withdrawal risk, the challenge is appetite returning before your habits are ready. Here is the structured way through.

Hourglass on pebbles

What happens when you stop

Semaglutide clears your system over 5 to 7 weeks. Appetite returns gradually, and most people notice food thoughts growing louder across the first two months. STEP 4 gives the plain data: without a maintenance structure, most people regained much of their loss within a year of stopping. With structure, the story is different.

The taper options

Step-down taper (most common)

Drop one dose level every 4 to 8 weeks, 2.4 mg to 1.7 mg to 1 mg to 0.5 mg, then stop. Each step is rehearsal for eating with slightly more appetite.

Switch to tablets first

Some people move to Wegovy tablets at a moderate dose, then taper the tablet. A daily ritual can ease the psychological transition from "treatment" to "no treatment".

Stopping directly

Medically safe. There is no dependence. It simply skips the rehearsal period, so we reserve it for situations that require a quick stop.

A realistic stopping timeline

WeeksPhaseFocus
1 to 4First step downProtein target and meal structure locked while appetite stays muted
5 to 12Continued taperPortion habits practised at rising appetite. Weekly weigh-ins
13 to 16Final doseStrength routine established. Maintenance calories agreed
17 onwardOff treatmentMonthly weigh-ins. Check-ins at 3 and 6 months

If weight starts returning

Act at a 2 to 3 kg uptrend, not a 10 kg slide. Options: tighten structure, return to a low dose for a defined period, or restart formally. Restarting after a break may mean a lower starting dose, tolerance fades over weeks off treatment.

Continue reading

Wegovy pen with box

Wegovy plan from £69 a month

Weekly injection, semaglutide. Price covers the medicine, prescriber review, monthly check-ins and tracked delivery.

See the Wegovy plan

Check if treatment suits youFree health check. You pay nothing until a prescriber approves.

Check your eligibility

About this page

Written by
Able Clinic editorial team
Clinical review
Pharmacy team at Curb Healthcare Ltd, GPhC 9012581
Last reviewed

Each page is checked against the UK licence for the medicine. Read our editorial policy.

Sources

  1. NICE TA875: semaglutide for managing overweight and obesity
  2. STEP 1 trial, New England Journal of Medicine 2021
  3. SELECT trial (cardiovascular outcomes), NEJM 2023
  4. Electronic medicines compendium: Wegovy product information
  5. MHRA Yellow Card scheme
  6. STEP 4 trial (semaglutide withdrawal), JAMA 2021
Check your eligibility